Literature DB >> 19617716

The MUS81 endonuclease is essential for telomerase negative cell proliferation.

Sicong Zeng1, Qin Yang.   

Abstract

A substantial number of human tumors (approximately 10%) are telomerase negative, and cells in such tumors have been proposed to maintain telomere length by the alternative lengthening of telomeres (ALT) pathway. Although details of the molecular mechanism of ALT are largely unknown, previous studies have shown that telomere homologous recombination (HR) is implicated in the ALT pathway. MUS81 is a DNA structure-specific recombination endonuclease and functions on aberrant DNA replication and recombination. Recently, we demonstrate that MUS81 plays a key role in the maintenance of telomeres in ALT cells (Zeng, et al. Nature Cell Biology, 2009). The MUS81 endonuclease specifically localizes to ALT-associated promyelocytic leukemia nuclear bodies (APBs) and interacts with telomeres in ALT cells. Depletion of MUS81 leads to reduced telomere recombination resulting in the growth arrest of ALT cells. The endonuclease activity of MUS81, regulated by its binding partner TRF2, is found to be essential for telomere post-replicative recombination. This study provides the first direct evidence that MUS81 specifically functions on ALT recombination-based cell survival. The specific function of MUS81 on the ALT pathway provides a potential powerful diagnostic marker and a therapeutic target for ALT tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617716     DOI: 10.4161/cc.8.14.9149

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  BLM and SLX4 play opposing roles in recombination-dependent replication at human telomeres.

Authors:  Alexander P Sobinoff; Joshua Am Allen; Axel A Neumann; Sile F Yang; Monica E Walsh; Jeremy D Henson; Roger R Reddel; Hilda A Pickett
Journal:  EMBO J       Date:  2017-09-06       Impact factor: 11.598

2.  Multiple Mechanisms Contribute To Telomere Maintenance.

Authors:  Tammy A Morrish; Dulat Bekbolysnov; David Velliquette; Michelle Morgan; Bryan Ross; Yongheng Wang; Benjamin Chaney; Jessica McQuigg; Nathan Fager; Ira P Maine
Journal:  J Cancer Biol Res       Date:  2013-11-19

3.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

4.  Telomerase enzymatic component hTERT shortens long telomeres in human cells.

Authors:  Yun-Ling Zheng; Fan Zhang; Bing Sun; Juan Du; Chongkui Sun; Jie Yuan; Ying Wang; Lian Tao; Krishna Kota; Xuefeng Liu; Richard Schlegel; Qin Yang
Journal:  Cell Cycle       Date:  2014-04-10       Impact factor: 5.173

5.  The alternative lengthening of telomeres mechanism jeopardizes telomere integrity if not properly restricted.

Authors:  Bruno Silva; Rajika Arora; Claus M Azzalin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-19       Impact factor: 12.779

6.  Substrate specificity of the MUS81-EME2 structure selective endonuclease.

Authors:  Alessandra Pepe; Stephen C West
Journal:  Nucleic Acids Res       Date:  2013-12-25       Impact factor: 16.971

Review 7.  Telomere maintenance mechanisms in cancer: clinical implications.

Authors:  Roger R Reddel
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.

Authors:  Chong-kui Sun; Fan Zhang; Tao Xiang; Qianming Chen; Tej K Pandita; Yuping Huang; Mickey C T Hu; Qin Yang
Journal:  Oncotarget       Date:  2014-05-30

9.  MUS81-EME2 promotes replication fork restart.

Authors:  Alessandra Pepe; Stephen C West
Journal:  Cell Rep       Date:  2014-05-09       Impact factor: 9.423

10.  Saccharomyces cerevisiae Mus81-Mms4 prevents accelerated senescence in telomerase-deficient cells.

Authors:  Erin K Schwartz; Shih-Hsun Hung; Damon Meyer; Aurèle Piazza; Kevin Yan; Becky Xu Hua Fu; Wolf-Dietrich Heyer
Journal:  PLoS Genet       Date:  2020-05-29       Impact factor: 5.917

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.